Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Craig B. Langman1,2 , Bruce A. Barshop3, Georges Descheˆnes4, Francesco Emma5, Paul Goodyer6,Graham Lipkin7, Julian P. Midgley8, Chris Ottolenghi9,10, Aude Servais11, Neveen A. Soliman12, Jess G. Thoene13 and Elena N. Levtchenko14,15; for Conference Participants16
Meeting Report – as Published in Kidney International, (2016) 89, 1192–1203, http://dx.doi.org/10.1016/j.kint.2016.01.033
Nephropathic cystinosis is an autosomal recessive metabolic, lifelong disease characterized by lysosomal cystine accumulation throughout the body that commonly presents in infancy with a renal Fanconi syndrome and, if untreated, leads to end-stage kidney disease (ESKD) in the later childhood years. The molecular basis is due to mutations in CTNS, the gene encoding for the lysosomal cystine-proton cotransporter, cystinosin. During adolescence and adulthood, extrarenal manifestations of cystinosis develop and require multidisciplinary care. Despite substantial improvement in prognosis due to cystine-depleting therapy with cysteamine, no cure of the disease is currently available. idney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on cystinosis to review the state-of-the-art knowledge and to address areas of controversies in pathophysiology, diagnostics, monitoring, and treatment in different age groups. More importantly, promising areas of investigation that may lead to optimal outcomes for patients afflicted with this lifelong, systemic disease were discussed with a research agenda proposed for the future.
Full Publication: KDIGO-Cystinosis-Conf-Report-Final